menu
    • menu
    [{"orgOrder":0,"company":"SYMYOO Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Clomipramine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"SYMYOO Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SYMYOO Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SYMYOO Inc \/ Undisclosed"},{"orgOrder":0,"company":"SYMYOO Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Clomipramine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"SYMYOO Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SYMYOO Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SYMYOO Inc \/ Undisclosed"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Obsessive Compulsive Foundation | Centre for Addiction and Mental Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Clomipramine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sunnybrook Health Sciences Centre \/ Obsessive Compulsive Foundation | Centre for Addiction and Mental Health","highestDevelopmentStatusID":"1","companyTruncated":"Sunnybrook Health Sciences Centre \/ Obsessive Compulsive Foundation | Centre for Addiction and Mental Health"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Clomipramine Hydrochloride","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alembic Pharmaceuticals Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Anaphranil

    Menu

    Anaphranil

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alembic Pharmaceuticals Limited

                            India arrow
                            AllPack Indonesia
                            Not Confirmed

                            Alembic Pharmaceuticals Limited

                            India arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clomipramine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Alembic Pharma Gets Final Approval from USFDA for OCD Treatment Drug

                            Details : Clomipramine Hydrochloride Capsules are indicated for the treatment of obsessions and compulsions in patients with OCD.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 05, 2021

                            Lead Product(s) : Clomipramine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SYMYOO Inc

                            South Korea arrow
                            AllPack Indonesia
                            Not Confirmed

                            SYMYOO Inc

                            South Korea arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clomipramine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Trial of PED-1 in Male Patients With Premature Ejaculation

                            Details : Clomipramine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Premature Ejaculation.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 23, 2011

                            Lead Product(s) : Clomipramine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sunnybrook Health Sciences Centre

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed

                            Sunnybrook Health Sciences Centre

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clomipramine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Undisclosed

                            Sponsor : Obsessive Compulsive Foundation | Centre for Addiction and Mental Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Predicting Medication Response in Obsessive Compulsive Disorder

                            Details : Clomipramine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Obsessive-Compulsive Disorder.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 28, 2011

                            Lead Product(s) : Clomipramine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Undisclosed

                            Sponsor : Obsessive Compulsive Foundation | Centre for Addiction and Mental Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            SYMYOO Inc

                            South Korea arrow
                            IPEX Indonesia
                            Not Confirmed

                            SYMYOO Inc

                            South Korea arrow
                            IPEX Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clomipramine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 2 Trial of PED-1 and PED-2 in Male Patients With Premature Ejaculation

                            Details : Clomipramine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Premature Ejaculation.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 16, 2010

                            Lead Product(s) : Clomipramine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth